
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Asklepios BioPharmaceutical | NAN-101 | congestive heart failure | phase 1 trial dosing first patient |
Immix Biopharma | Imx-110 | advanced solid tumors | phase 1b/2a trial dosing first patient in U.S. |
Moleculin Biotech | Liposomal Annamycin (annamycin) | relapsed or refractory acute myeloid leukemia | phase 1 trial completed |
AIVITA Biomedical | AV-GBM-1 | glioblastoma | phase 2 trial enrollment completed |
Alkahest | AKST4290 | Parkinson’s Disease | phase 2 trial dosing first patient |
Minerva Neurosciences | roluperidone | schizophrenia | phase 3 trial enrolling 515 patients in the U.S. and Europe |
INVO Bioscience | INVOcell | infertility | phase 3 trial enrolling 180 patients at three sites in the U.S. |
VistaGen Therapeutics | AV-101 | dyskinesia in Parkinson's Disease patients | phase 2 IND awarded by the FDA |
GlycoMimetics | GMI-1359 | osteosarcoma | Orphan Drug and Rare Pediatric Disease designations granted by the FDA |
Aria CV | Aria CV Pulmonary Hypertension System | pulmonary arterial hypertension | Breakthrough Device designation awarded by the FDA |
ReAlta Life Sciences | PIC1-dPEG24 | hypoxic-ischemic encephalopathy in neonates | Orphan Drug designation awarded by the FDA |
EyeYon Medical | EndoArt film implant | chronic corneal edema secondary to endothelial dysfunction | Breakthrough Device designation awarded by the FDA |
VIVUS | PANCREAZE (pancrelipase) Delayed Release Capsules | exocrine pancreatic insufficiency due to cystic fibrosis or other conditions | supplemental NDA approved by the FDA |
Seqirus | Audenz vaccine | potential pandemic associated with the H5N1 flu virus | approved by the FDA |
Aimmune Therapeutics | Palforzia (AR101) | pediatric patients, ages 4 to 17, who have an allergy to peanuts | approved by the FDA |
Upcoming Events
-
05Dec
-
14Apr